In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Indian Court Blocks Sinopharm Weiqida Over Centrient's Amoxicillin

Executive Summary

India’s High Court in Delhi has issued an injunction restraining China’s Sinopharm Weiqida from exporting, importing and selling its amoxicillin trihydrate in India, as it infringes Centrient’s patent. Sinopharm Weiqida has also been found guilty of contempt of court for failing to follow a preliminary injunction order that was issued in April 2017.

You may also be interested in...

Centrient Slaps Dalas With Second Amoxicillin Lawsuit

Netherlands-based Centrient Pharmaceuticals, a global leader in producing “sustainable” enzymatic antibiotics, next-generation statins and antifungals, has filed a second lawsuit against Indian company Dalas Biotech accusing it of patent infringement.

Centrient Accuses India’s Dalas Of Amoxicillin Patent Infringement

Centrient Pharmaceuticals, which makes “sustainable antibiotics,” has filed an Indian lawsuit in the Delhi High Court against Dalas Biotech accusing the Indian company of patent infringement over its amoxicillin trihydrate API.

DSM Sinochem Pharmaceuticals Announces Name Change To Centrient Pharmaceuticals

Changing its name to Centrient Pharmaceuticals marks the next phase in DSM Sinochem Pharmaceuticals’ “strategic evolution” as a global generics pharmaceutical company, in a move resulting from its recent takeover by Bain Capital.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts